Elisa Tavanti
Overview
Explore the profile of Elisa Tavanti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
313
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fanelli M, Tavanti E, Patrizio M, Vella S, Fernandez-Ramos A, Magagnoli F, et al.
Front Oncol
. 2020 Mar;
10:331.
PMID: 32211337
Treatment of high-grade osteosarcoma, the most common malignant tumor of bone, is largely based on administration of cisplatin and other DNA damaging drugs. Altered DNA repair mechanisms may thus significantly...
2.
Tisato V, Romani A, Tavanti E, Melloni E, Milani D, Bonaccorsi G, et al.
Antioxidants (Basel)
. 2019 Aug;
8(8).
PMID: 31390816
Paraoxonase 1 (PON1) is a high-density lipoprotein (HDL)-associated protein that endows its carrier with (lipo-)lactonase-dependent antioxidative features. Low levels of PON1 activity have been observed in association with obesity, a...
3.
Buondonno I, Gazzano E, Tavanti E, Chegaev K, Kopecka J, Fanelli M, et al.
Cell Mol Life Sci
. 2018 Nov;
76(3):609-625.
PMID: 30430199
Doxorubicin is one of the most effective drugs for the first-line treatment of high-grade osteosarcoma. Several studies have demonstrated that the major cause for doxorubicin resistance in osteosarcoma is the...
4.
Hattinger C, Patrizio M, Tavanti E, Luppi S, Magagnoli F, Picci P, et al.
Expert Rev Mol Diagn
. 2018 Oct;
18(11):947-961.
PMID: 30324828
Genetic characterization of osteosarcoma has evolved during the last decade, thanks to the integrated application of conventional and new candidate-driven and genome-wide technologies. Areas covered: This review provides an overview...
5.
Hattinger C, Fanelli M, Tavanti E, Vella S, Riganti C, Picci P, et al.
Future Oncol
. 2017 Feb;
13(8):673-677.
PMID: 28183198
No abstract available.
6.
Vella S, Tavanti E, Hattinger C, Fanelli M, Versteeg R, Koster J, et al.
PLoS One
. 2016 Nov;
11(11):e0166233.
PMID: 27898692
Cyclin-dependent kinase 2 (CDK2) has been reported to be essential for cell proliferation in several human tumours and it has been suggested as an appropriate target to be considered in...
7.
Hattinger C, Vella S, Tavanti E, Fanelli M, Picci P, Serra M
Pharmacogenomics
. 2016 Nov;
17(18):2097-2114.
PMID: 27883291
Second-line treatment of high-grade osteosarcoma (HGOS) patients is based on different approaches and chemotherapy protocols, which are not yet standardized. Although several drugs have been used in HGOS second-line protocols,...
8.
Hattinger C, Tavanti E, Fanelli M, Vella S, Picci P, Serra M
Expert Opin Drug Metab Toxicol
. 2016 Oct;
13(3):245-257.
PMID: 27758143
Antifolates are structural analogs of folates, which have been used as antitumor drugs for more than 60 years. The antifolate drug most commonly used for treating human tumors is methotrexate...
9.
Hattinger C, Biason P, Iacoboni E, Gagno S, Fanelli M, Tavanti E, et al.
Oncotarget
. 2016 Aug;
7(38):61970-61987.
PMID: 27566557
This study aimed to identify associations between germline polymorphisms and risk of high-grade osteosarcoma (HGOS) development, event-free survival (EFS) and toxicity in HGOS patients treated with neo-adjuvant chemotherapy and surgery.Germline...
10.
Fanelli M, Hattinger C, Vella S, Tavanti E, Michelacci F, Gudeman B, et al.
Curr Cancer Drug Targets
. 2015 Nov;
16(3):261-74.
PMID: 26548759
Clinical treatment response achievable with conventional chemotherapy in high-grade osteosarcoma (OS) is severely limited by the presence of intrinsic or acquired drug resistance, which in previous studies has been mainly...